Mark W Taylor, MD | |
4700 Point Fosdick Drive Nw, Ste 112, Gig Harbor, WA 98335 | |
(253) 759-5555 | |
(253) 830-5420 |
Full Name | Mark W Taylor |
---|---|
Gender | Male |
Speciality | Ophthalmology |
Location | 4700 Point Fosdick Drive Nw, Gig Harbor, Washington |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1558393595 | NPI | - | NPPES |
8194854 | Medicaid | WA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207W00000X | Ophthalmology | 33887 (Washington) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mark W Taylor, MD 3602 S 19th Street, Tacoma, WA 98405 Ph: (253) 759-5555 | Mark W Taylor, MD 4700 Point Fosdick Drive Nw, Ste 112, Gig Harbor, WA 98335 Ph: (253) 759-5555 |
News Archive
Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced that it has launched pamidronate disodium injection in single-dose vials containing 30 mg per 10 mL and 90 mg per 10 mL. Pamidronate disodium injection, the generic alternative of Novartis Pharmaceutical Company's Aredia®, is a bone resorption inhibitor. The 2008 U.S. market for pamidronate disodium approximated $17 million, according to IMS data.
A recent study, available on the bioRxiv* preprint server, investigated the durability of cellular immune memory after mRNA vaccination against SARS-CoV-2 and whether booster jabs affect the durability of different immune response components. The study included testing for antibodies and cellular immune responses in covid patients and recovered individuals.
This entire year was marked by an abundance of media coverage and attention surrounding prescription painkillers, largely the result of widespread misuse throughout Hollywood.
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced the availability of the first clinical test panel for aiding the diagnosis of suspected dementia due to treatable forms of cognitive impairment. The test panel is believed to be the first commercial service from a clinical laboratory to combine several guideline-recommended tests for identifying secondary, treatable causes of dementia as a single blood test and report.
› Verified 1 days ago
Preston Sullivan, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 5201 Olympic Dr Ste 110, Gig Harbor, WA 98335 Phone: 253-432-3238 Fax: 253-509-0217 |